logo
episode-header-image
Jun 2021
11m 52s

FDA Approves Aducanumab — A Controversia...

NPR
About this episode
The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it.

For more of Jon's reporting, read "For Those Facing Alzheimer's, A Controversial Drug Offers Hope."

You can email Short Wave at ShortWave@NPR.org.

See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.

NPR Privacy Policy
Up next
May 1
Coffee is complex. Can science standardize it for the better?
Ask any coffee aficionado, and they’ll tell you: A good cup is about more than the beans. The flavor is affected by lots of things – the roast and fermentation of the beans, the coarseness of the grind, the brewing temperature and even the chemicals in the water used to brew it. ... Show More
10m 10s
Apr 29
NASA is practicing moonwalks. When are we going back?
After the success of Artemis II, we at Short Wave definitely have moon fever. So, we brought NPR science correspondent Nell Greenfieldboyce onto the show to talk about where we’re headed. What will future Artemis missions look like and what needs to happen next for people to be a ... Show More
9m 59s
Apr 28
Set up solar, or save a tree? It’s complicated
To solar or not to solar? That is the question for this latest episode of our monthly series Nature Quest. For listener Darcey Hughes, installing solar panels isn’t just about keeping her utilities free of fossil fuels – it’s also a way to become fully self-reliant and save some ... Show More
12m 26s
Recommended Episodes
Aug 2021
Controversial new Alzheimer's drug in the spotlight
After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More
18m 21s
Jul 2021
'Some Hope Is Better Than Having No Hope'
<p>When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.</p><p>But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cogni ... Show More
36m 59s
May 2024
This Is a Very Weird Moment in the History of Drug Laws
<p>Drug policy feels very unsettled right now. The war on drugs was a failure. But so far, the war on the war on drugs hasn’t entirely been a success, either.</p><p>Take Oregon. In 2020, it became the first state in the nation to decriminalize hard drugs. It was a paradigm shift ... Show More
1h 2m
Dec 2022
Declining ALS Patients Are Waiting On The FDA's Next Move
For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ... Show More
25m 57s